MiniMed
Company Snapshot
MiniMed is a company focused on diabetes management solutions, primarily through its integrated systems that include insulin pumps and continuous glucose monitoring (CGM) devices. The company aims to enhance the quality of life for people with diabetes by providing advanced technology that simplifies diabetes management. Their business model is centered around selling these devices and related consumables, generating recurring revenue from a growing base of users.
Key Financials
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $2,715M | $2,715M | $2,469M |
| YoY Growth | +0.0% | +10.0% | - |
| Adjusted Net Loss | -$198M | -$198M | -$107M |
| Margin % | -7.3% | -7.3% | -4.3% |
Balance Sheet
Implied Valuation at Midpoint
Based on price range midpoint and most recent fiscal year data.
S-1 Highlights
Market & Competition
The company operates in the diabetes management market, competing with Medtronic, Abbott, and other companies in the sector. The market is characterized by rapid technological advancements and increasing demand for integrated diabetes solutions.
Use of Proceeds
Proceeds from the IPO will be used to maintain approximately $350 million in cash for general corporate purposes, repay intercompany debt owed to Medtronic, and potentially pay additional consideration for assets transferred during the Separation.
Key Risk Factors
- ●The company may face challenges in successfully executing the Separation and divestment transactions with Medtronic, which could impact its financial condition.
- ●Intense competition in the diabetes management market could hinder the company's ability to grow its market share and maintain profitability.
Deal Structure
Reported Broker Availability
Fidelity
TD AmeritradeReported by users or publicly disclosed. Information is for reference only.